Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Hepatology. 2014 May 14;60(1):37–45. doi: 10.1002/hep.27151

Table 1.

Cost savings per SVR with SOF/SMV: Base case and sensitivity analyses

Scenario Cost per SVR
(SOF/RBV)
Cost per SVR
(SOF/SMV)
Cost savings per SVR
with SOF/SMV
Base case $262,046 $170,456 $91,590
Sensitivity Analyses
  Disease characteristics
    Advanced fibrosis (Metavir stage F3/F4) only $284,407 $186,968 $97,439
    Genotype 1/subtype A with Q80K polymorphism only (all fibrosis stages) $262,046 $188,856 $73,190
  SVR rates*
    Low SOF/SMV; high SOF/RBV $221,156 $175,450 $45,706
    High SOF/SMV; low SOF/RBV $312,160 $162,404 $149,756
    High SOF/SMV; base case SOF/RBV $262,046 $162,404 $99,642
    Low SOF/LDV $265,425 $170,494 $94,931
  Tolerability
    Doubled likelihood of adverse events during treatment $262,171 $170,463 $91,708
  Retreatment
    Cost of SOF/LDV rescue therapy set at $0 per treatment $194,347 $165,432 $28,915
    Decreased proportion retreated after initial failure* $261,081 $169,965 $91,116
*

See Table 4 for low and high SVR thresholds for each drug regimen, and for low threshold for proportion retreated after initial failure.

F3/F4 = Metavir fibrosis stages 3 and 4; LDV = ledipasvir; RBV = ribavirin; SMV = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; Q80K = a naturally occurring polymorphism found in up to 47% of HCV genotype 1/subtype A infected individuals and less commonly in those with HCV genotype 1/subtype B; the presence of this polymorphism has been associated with lower SVR rates in subjects treated with simeprevir in combination with other drugs.